Trump Administration Signals Deference To Congress On Drug Pricing Policy

In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.

Man on a mountain peak looking through binoculars to a red flag. The concept of reaching goals.
We're A Long Way From There

President Trump’s proposed federal budget for 2021 projects $135bn in savings over 10 years from enactment of “comprehensive drug pricing reform” without offering concrete plans for generating the savings.

The figure is described as an allowance for “bipartisan drug pricing proposals” in the budget proposal released 10 February. In...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Pricing Debate

More from Market Access